OSE Immunotherapeutics Seeks Partner For Lead Drug

 
• By Lucie Ellis-Taitt

Emerging Company Profile: Alexis Peyroles, chief operating officer of OSE Immunotherapeutics outlines the 2016-founded company's plans for commercializing its lead drug, Tedopi (OSE-2102).

Emerging Company Profile Regular column feature image Version 2
OSE Immunotherapeutics targets lead drug at NSCLC patients that don't benefit from PD-1s

More from Start-Ups & SMEs

More from Business